2L
MRNA icon

25 LLC’s Moderna MRNA Stock Holding History

25 LLC’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-8
Closed -$1.01K – 352
2023
Q2 		$1.01K Buy
+8
New +$1.07K ﹤0.01% 289

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

25 LLC's MRNA Position: Q3 2023 in Review

25 LLC sold out of Moderna (MRNA) in Q3 2023, closing a stake of 8 shares — an estimated $1.01K sold.

25 LLC first reported a position in MRNA in Q2 2023 and held it in 1 quarter. The position peaked at $1.01K in Q2 2023. 889 funds tracked by Wall St. Rank hold MRNA as of Q3 2023.

  • 25 LLC reported no remaining Moderna position as of Q3 2023 after selling out during the quarter.
  • 25 LLC sold 8 Moderna shares in Q3 2023, an estimated $1.01K.
  • 25 LLC first reported a position in Moderna in Q2 2023 and held it in 1 quarter.
  • 25 LLC's Moderna position peaked at $1.01K in Q2 2023.
  • 889 funds tracked by Wall St. Rank held Moderna as of Q3 2023.

Based on 25 LLC's 13F filing for Q3 2023, filed 18 Oct 2023.